Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cybin Inc (NY: CYBN ) 8.840 -0.060 (-0.67%) Official Closing Price Updated: 8:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cybin Inc < Previous 1 2 3 4 5 6 7 8 9 ... 38 39 Next > Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder October 03, 2023 From Cybin Inc. Via Business Wire Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... Via Benzinga InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study September 27, 2023 Via Investor Brand Network What 11 Analyst Ratings Have To Say About Cybin September 01, 2023 Via Benzinga Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder September 27, 2023 From Cybin Inc. Via Business Wire Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression September 26, 2023 Clinical-stage psychedelics biotech Cybin Inc. Via Benzinga Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results September 26, 2023 New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. Via Benzinga Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Via Benzinga Topics Economy Exposures Interest Rates Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial September 26, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference September 25, 2023 Via Investor Brand Network Cybin to Participate in the Cantor Global Healthcare Conference September 25, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting September 22, 2023 Via Investor Brand Network Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression September 21, 2023 Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... Via Benzinga Cybin Announces Date of Annual and Special Meeting of Shareholders September 21, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study September 21, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder September 21, 2023 From Cybin Inc. Via Business Wire Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise September 20, 2023 EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Intellectual Property Exposures Death Intellectual Property Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket September 20, 2023 Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday. Via Benzinga Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket September 19, 2023 Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 73.5% to $0.1313 in pre-market trading after falling 15% on Monday. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday September 19, 2023 Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning! Via InvestorPlace Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update September 18, 2023 Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). Via Benzinga The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023 September 14, 2023 Cheap valuations and prospects for future growth should get individual investors excited for these under-$1 stocks to buy. Via InvestorPlace NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years September 12, 2023 NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. Via Benzinga Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT September 05, 2023 The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More September 05, 2023 Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Via Benzinga InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Approval for U.S. Patent Covering Deuterated Tryptamines September 05, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines September 05, 2023 From Cybin Inc. Via Business Wire Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions August 31, 2023 Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... Via Benzinga Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M August 29, 2023 Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 38 39 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.